History 2021 2021 Evotec announces Bristol Myers Squibb opt-in of EVT8683 as the first programme from iPSC-based neurodegeneration collaboration Just - Evotec Biologics opens J.POD® 1 US in Redmond, Washington Positive Phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough Evotec launches “beLAB1407” in collaboration with Bristol Myers Squibb Evotec launches “beLAB2122” in collaboration with Bristol Myers Squibb Implementation of Action Plan 2025 “The data-driven R&D Autobahn to Cures” Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance Evotec and Chinook Therapeutics enter into strategic collaboration to discover and develop novel precision medicines for chronic kidney diseases Evotec starts clinical development of Chikungunya antibody 2020 2020 Mubadala Investment Company and Novo Holdings A/S invest € 250 m in Evotec SE Evotec and Novo Nordisk form strategic alliance to develop novel therapies for kidney diseases Evotec and Secarna Pharmaceuticals form strategic partnership in the field of antisense therapy Just - Evotec Biologics to produce monoclonal antibody products against COVID-19 for the Department of Defense Evotec, Samsara BioCapital, and KCK launch Autobahn Labs Evotec regains global rights to beta cell replacement therapy Evotec expands into gene therapy with the dedicated site Evotec GT in Austria Just – Evotec Biologics initiates construction of first J.POD facility in North America and enters into multi-year collaboration with MSD around facility of the future Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome 2019 2019 Evotec and Vifor Pharma form joint venture for early development in nephrology Evotec, Integra Holdings and Yissum establish LAB555 Evotec and Takeda enter collaboration agreement to discover clinical candidates across multiple therapeutic areas P2X3 antagonist demonstrates efficacy against refractory chronic cough in Phase II (POC) Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH" Evotec SE places first Schuldschein (Promissory note) worth € 250 m Evotec, Sensyne Health, the University of Oxford, OSI, and OUI create new bridge partnership “LAB10x” in digital health Evotec jump-starts biologics with acquisition of Just Biotherapeutics Evotec AG is converted into Evotec SE Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer Evotec and Galapagos enter into collaboration in the field of fibrosis Evotec reaches important scientific achievement within iPSC-based collaboration with Celgene 2018 2018 Evotec receives milestone payment for start of Phase II trial in its multi-target alliance with Bayer Evotec achieves second milestone in diabetes alliance with Sanofi Evotec and Sanofi sign definitive agreement to combat infectious diseases Evotec forms academic BRIDGE LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research Center Evotec and Celgene expand iPSC collaboration to include additional cell lines Evotec and Celgene enter into strategic oncology partnership Evotec and Bayer advance third endometriosis programme into Phase I clinical development Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi 2017 2017 Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim Evotec joins forces with academic leaders to accelerate drug discovery in kidney diseases and build NEPLEX Evotec achieves first milestone in neurodegeneration alliance with Celgene Evotec invests in Exscientia to advance AI-driven drug discovery Evotec and MaRS Innovation establish LAB150 in Toronto European Investment Bank supports Evotec´s Innovate strategy with € 75 m loan Evotec acquires Aptuit Evotec and Bayer advance endometriosis programme into Phase I clinical development and extend alliance Evotec announces strategic investment in Facio Therapies to support development of novel FSHD therapy Evotec joins NURTuRE consortium to mine unique kidney disease patient biobank Evotec achieves first milestone in Diabetes alliance (TargetBCD) with Sanofi Novo A/S becomes new long-term strategic shareholder in Evotec Evotec and Eternygen to develop novel metabolic disease therapy, Evotec participate in Eternygen's Series A funding 2016 2016 Multi-year drug discovery collaboration for neurodegenerative diseases with Celgene based on Evotec`s iPSC platform Evotec acquired Cyprotex, a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in the UK Evotec and Oxford University create novel Partnership called 'LAB282' Evotec and Carrick Therapeutics build strategic alliance, Evotec contributes to funding round Evotec enters into strategic multi-target alliance with C4X Discovery Evotec and Bayer partner to develop new treatments to fight kidney diseases Start of first Phase I within Endometriosis alliance with Bayer Evotec and Ellersbrook join forces to accelerate development of TargetNASH Evotec extends integrated drug discovery alliance with Genentech Evotec and ex scientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics (TargetBiSM) Position cemented as the world leader in outsourced compound management through new agreements with UCB and Pierre Fabre Evotec spins off auto-immune disease company as 'Topas Therapeutics GmbH' Evotec awarded grant from The Michael J. Fox Foundation for Parkinson's Research (TargetaSN) 2015 2015 Evotec receives important pre-clinical milestones as part of its multi-target alliance with Bayer Evotec enters into licence and collaboration agreement with Pfizer Inc. in tissue fibrosis (TargetFibrosis) Evotec and CHDI Foundation expand ongoing collaboration to fight Huntington's disease Evotec, Apeiron Biologics and Sanofi jointly develop novel small molecule-based cancer immunotherapies (TargetImmuniT) Sanofi and Evotec align forces to develop next generation therapies in diabetes (TargetBCD) Evotec's partner Roche announced that Sembragiline (RG1577, EVT302), a MAO-B inhibitor for the treatment of Alzheimer's disease failed to demonstrate benefit on the primary endpoint Evotec and Sanofi sign definitive agreement for major mulit-component strategic alliance and acquires Sanofi's scientific operations and related employees at Toulouse site Second Genome and Evotec to collaborate in microbiome discovery and development (TargetMB) Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration 2014 2014 Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease Termination of the development of DiaPep277® (one of Evotec's advanced partnered pipeline projects) by Hyperion Therapeutics, Inc. Twenty three milestones achieved as part of the collaboration with Boehringer Ingelheim Evotec establishes an anti-infectives platform with the acquisition of Euprotec Ltd Evotec acquires Bionamics GmbH to accelerate EVT Innovate strategy 2013 2013 Evotec and Yale University to collaborate on cancer therapy (TargetDBR) Evotec announces TargetAD collaboration with Johnson & Johnson Innovation to identify and develop novel Alzheimer's disease therapies Evotec and Harvard University to collaborate on exploration of enteroendocrine signals affecting key metabolic pathways (TargetEEM) Evotec and Harvard Stem Cell Institute form CureMN collaboration to advance ALS research Evotec and Harvard University to collaborate on development of new class of antibacterials (TargetPGB) Dana-Farber's Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology (TargetKDM) Evotec extends drug discovery alliance with Genentech Evotec acquires Cell Culture Service GmbH Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy (TargetImmuniT) 2012 2012 Evotec partners its EVT100 series with Janssen Pharmaceuticals Evotec partners with Haplogen to develop drugs for infectious diseases (TargetPicV) Evotec extends ongoing collaboration with CHDI Foundation Evotec and Bayer enter into long-term, multi-target alliance to fight Endometriosis NIH awards major contract to Evotec to manage and operate a small molecule repository Evotec and Harvard University enter first academic bridge alliance with Janssen Pharmaceuticals (CureBeta) Evotec grants exclusive rights on EVT401 in China to CONBA Pharmaceutical Evotec Action Plan 2016 – Innovation Efficiency Evotec and Harvard University expand strategic alliance into Kidney Disease (CureNephron) 2011 2011 Evotec and Roche sign an agreement to develop compound (EVT302) against Alzheimer’s disease Start of multi-target collaboration with UCB in neurodegenerative and neurological diseases and in the field of immunology Evotec and Roche to jointly develop biomarkers in oncology Evotec acquires compound management business from Galapagos and further strengthens its innovation offering Evotec and Roche decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT101 Evotec acquires Kinaxo, expanding its drug discovery platform with cutting-edge technologies Evotec establishes research collaboration with Harvard University and the Howard Hughes Medical Institute in diabetes research (CureBeta) 2010 2010 Evotec entered into a licence and collaboration agreement with MedImmune in the diabetes therapeutic area with a particular focus on the regeneration of insulin producing beta cells Evotec licenses Phase II insomnia (EVT201) candidate to JingXin Pharma for development in China Evotec is adding a core capability in metabolic disease biology by acquiring DeveloGen Start of Phase II with EVT101 (Treatment-resistant depression) in collaboration with Roche Start of integrated long-term drug discovery alliance with Genentech Extension of CHDI collaboration 2009 2009 TecDAX re-entry/Evotec voluntarily delists from NASDAQ Evotec and Boehringer Ingelheim extend and broaden research collaboration Start of Phase I with EVT103 (Treatment-resistant depression) in collaboration with Roche Evotec accelerates growth strategy of its discovery alliance business with acquisition of Indian RSIPL Successful Completion of first Phase I Study with EVT401 (P2X7) Evotec acquires Zebrafish Screening Operations of Summit Corporation Evotec Restructures and Implements Evotec 2012 - Action Plan to Focus and Grow Evotec and Roche to develop EVT101 for treatment-resistant depression 2008 2008 Three-year drug discovery collaboration with Novartis Start Phase I with P2X7 Antagonist (EVT401) in inflammatory disease Evotec completes acquisition of Renovis, NASDAQ-Listing 2007 2007 Evotec sells its Chemical Development Business to Aptuit Evotec and Research Support International Limited form Evotec-RSIL Ltd, a Joint Venture in India for the design, synthesis, management and commercialisation of compound libraries Positive results in two Phase II trials with EVT201 in insomnia 2006 2006 Evotec sells Evotec Technologies to PerkinElmer Start of multi-year drug discovery alliance with CHDI on Huntington disease Forming a global alliance with Roche to jointly discover and develop compounds in the area of CNS Extension of global medicinal chemistry agreement and medicinal chemistry collaboration in oncology with Roche Successful completetion of Phase I for potential Alzheimer's Disease treatment, EVT101 Further expansion and extension of Boehringer Ingelheim drug discovery collaboration Evotec in-licenses two Phase I MAO-B inhibitor from Roche with disease modifying potential in Alzheimer's Disease 2005 2005 Capital increase, EUR 28.4 m Extension of medicinal chemistry agreement with Roche 2004 2004 Start of multi-year, multi-target drug discovery alliance with Boehringer Ingelheim Strategic global medicinal chemistry agreement with Roche Evotec Neurosciences to licence NMDA receptor NR2B subunit selective antagonists from Roche 2003 2003 Evotec Neurosciences and Takeda enter into a four-year collaboration to identify novel Alzheimer's disease targets 2002 2002 Spinning off its technology development business into its subsidiary Evotec Technologies Extension of Discovery Chemistry Agreement with Roche 2001 2001 Initial service collaborations with Eli Lilly, Merck, Novartis and Roche 2000 2000 Merge with Oxford Asymmetry International plc, form Evotec OAI AG, to become the leader in the discovery and development of novel small molecule drugs Successful market introduction of EVOscreen® 1999 1999 In November, Evotec BioSystems AG goes public Establishes Evotec Neurosciences GmbH in Hamburg 1998 1998 Raising DM 46 m (EUR 23.5 m), the largest private placements seen in the European biotech sector 1996 1996 Collaborations with Novartis and SmithKlineBeecham to develop EVOscreen® (High-Throughput Screening System) 1993 1993 Evotec BioSystems GmbH was founded in Hamburg, Germany. Among the founders were Nobel Laureate Professor Manfred Eigen, Dr Karsten Henco, Dr Ulrich Aldag, Dr Freimut Leidenberger, Dr Heinrich Schulte, Professor Rudolf Rigler and Dr Charles Weissmann TOP RSS Twitter LinkedIn EVOTEC @Evotec A new approach to off-the-shelf cancer vaccines - https://t.co/4Re4h5FDGx | Our latest blog details Dendritic Cells… https://t.co/xB7m0D5k8k 02:08 PM - 24 NOVEMBER 2021